Skip to main content

TARGETED NANOMEDICINE TO REVERSE FIBROSIS IN ISCHEMIC CARDIOMYOPATHIES

PCI2023-143431

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Afrontar las Prioridades de Nuestro Entorno
Subprogram Subprograma Estatal de Internacionalización
Call Proyectos Programación Conjunta Internacional
Call year 2023
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUT DE RECERCA DE L HOSPITAL DE LA SANTA CREU I SANT PAU

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Small Extracellular Vesicles in the Pericardium Modulate Macrophage Immunophenotype in Coronary Artery Disease

  • Ben-Aicha Gonzalez, Soumaya|||0000-0001-5572-5883
  • Anwar, M.
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Martino, F.
  • Kyriazis, P.G.
  • de Winter, N.
  • Punjabi, P.P.
  • Angelini, G.D.
  • Sattler, S.
  • Emanueli, Costanza|||0000-0002-2392-0702
Coronary artery disease (CAD) is a major health issue. This study focused on pericardial macrophages and small extracellular vesicles (sEVs) in CAD. The macrophages in CAD patients showed reduced expression of protective markers and unchanged levels of proinflammatory receptors. Similar changes were observed in buffy-coat-derived macrophages when stimulated with CAD pericardial fluid-derived sEVs. The sEV contained miRNA-6516-5p, which inhibited CD36 and affected macrophage lipid uptake. These findings indicate that sEV-mediated miRNA actions contribute to the decrease in protective pericardial macrophages in CAD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cardioprotection with intravenous statin administration during myocardial infarction vs. oral preloading, a preclinical study

  • Otero, Sergi|||0000-0002-2038-6882
  • Radikė, Monika|||0000-0002-4004-4150
  • Ben-Aicha Gonzalez, Soumaya|||0000-0001-5572-5883
  • Mendieta, Guiomar|||0000-0001-6652-9036
  • Gutiérrez, Manuel
  • Sutelman, Pablo|||0000-0002-4380-0900
  • Borrell-Pages, Maria|||0000-0002-1759-9756
  • Hidalgo, Alberto
  • Badimon, Lina|||0000-0002-9162-2459
  • Vilahur, Gemma|||0000-0002-2828-8873
Infarct size is associated with all-cause mortality and heart failure hospitalization underscoring the need for effective cardioprotection beyond timely reperfusion.1 Guidelines recommend administering high-potency statins early after ST-elevation myocardial infarction (STEMI) in order to reduce LDL-cholesterol levels as soon as possible.2 However, statins may provide clinical benefits in acute coronary syndrome patients beyond lipid-lowering effects. We have demonstrated in hypercholesterolaemic pigs through cardiac magnetic resonance (CMR) imaging and molecular/histological analyses that intravenous administration of a modified preparation of atorvastatin (i.v.-atorvastatin) during myocardial infarction (MI) limits ischaemia-related cardiac damage3,4 with a legacy effect that attenuates subsequent myocardial injury and preserves cardiac function during reinfarction.5 In addition, we have shown that this i.v.-atorvastatin approach exerts higher cardioprotective effects than those observed when atorvastatin is orally administered early after reperfusion.4 Furthermore, this new cardioprotective strategy is effective in the presence of comorbidities such as diabetic cardiomyopathy.6 However, it remains unknown whether i.v.-atorvastatin during ongoing MI provides superior cardioprotection compared to oral preloading therapy. Here we test this hypothesis in a highly translatable hypercholesterolaemic pig model using CMR.